Cost-Effectiveness of Ibrutinib for Chronic Lymphocytic Leukemia Treatment in India: Is Evidence Really at Crossroads?

This publication has 10 references indexed in Scilit:

• Evaluation of EuroQol Valuation Technology (EQ-VT) Designs to Generate National Value Sets: Learnings from the Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study
  Medical Decision Making, 2023
• Generic ibrutinib a potential cost-effective strategy for the first-line treatment of chronic lymphocytic leukaemia
  Annals of Hematology, 2023
• Protocol for estimating the willingness-to-pay-based value for a quality-adjusted life year to aid health technology assessment in India: a cross-sectional study
  BMJ Open, 2023
• What is the best method for long-term survival analysis?
  Indian Journal of Cancer, 2022
• Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set
  Value in Health, 2022
• National Methodological Guidelines to Conduct Budget Impact Analysis for Health Technology Assessment in India
  Applied Health Economics and Health Policy, 2021
• Adapting health technology assessment for drugs, medical devices, and health programs: Methodological considerations from the Indian experience
  Expert Review of Pharmacoeconomics & Outcomes Research, 2021
• Extrapolating Parametric Survival Models in Health Technology Assessment: A Simulation Study
  Medical Decision Making, 2020
• Chronic Lymphocytic Leukemia: Real-World Data From India
  JCO Global Oncology, 2020
• Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
  Leukemia, 2019